BETA Share Price Performance
₹1,730.20
492.72 (39.82%)
Price ₹1,730.20
Share Price₹1,730.20
BETA Community Narratives
There are no narratives available yet.
Recent BETA News & Updates
No updates
Beta Drugs Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 42.02
- Gross Margin
- 41.50%
- Net Profit Margin
- 11.71%
- Debt/Equity Ratio
- 67.3%
Beta Drugs Limited Competitors
About BETA
- Founded
- 2005
- Employees
- 371
- CEO
- WebsiteView website
Beta Drugs Limited develops, manufactures, and sells anti-cancer drugs in India. The company offers oncology products in the areas of breast, lung, head and neck, colorectal, ovarian, gastric, testicular, renal, and prostate cancer, as well as brain tumor, leukemia, lymphoma, myeloma, and supportive cancer; and dermatology products. It also develops active pharmaceutical ingredients. The company exports its products. Beta Drugs Limited was incorporated in 2005 and is based in Panchkula, India.
Indian Market Performance
- 7 Days: -1.7%
- 3 Months: 4.9%
- 1 Year: -4.7%
- Year to Date: -1.5%
Over the last 7 days, the market has dropped 1.7%, driven by a decline of 1.3% in the Communication Services sector. In the last 12 months the market is down 4.7%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading